PMID- 34667735
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211022
IS  - 2222-3959 (Print)
IS  - 2227-4898 (Electronic)
IS  - 2222-3959 (Linking)
VI  - 14
IP  - 10
DP  - 2021
TI  - Dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema: 
      real-world data versus clinical trials outcomes.
PG  - 1571-1580
LID - 10.18240/ijo.2021.10.15 [doi]
AB  - AIM: To investigate the safety and efficacy of intravitreal dexamethasone 
      implants (Ozurdex((R))/DEX) in patients with diabetic macular edema (DME) either 
      naive or non-naive to anti-VEGF therapies who switched to DEX implant independent 
      of response to anti-vascular endothelial growth factors (anti-VEGFs). METHODS: 
      This was an audit retrospective review of medical records of patients with DME 
      who switched to the DEX intravitreal implant. Patients were divided into 2 
      groups: patients naive to antiangiogenic therapy and patients who were previously 
      treated with anti-VEGFs. Data regarding demographics, changes in mean 
      best-corrected visual acuity (BCVA), central macular thickness (CMT), and 
      intraocular pressure (IOP) was collected over 6mo. The demographic data mean 
      changes in BCVA, CMT, and IOP were compared. Six-month follow-up data of 47 
      patients (57 eyes), who either switched to DEX implant irrespective of response 
      to previous treatments or were treatment naive before receiving DEX implant, was 
      collected. RESULTS: Improvement in mean BCVA was observed from 1-4mo after 
      injection with a decreased effect at month 6 as expected, with better outcomes in 
      naive compared to non-naive patients. A statistically relevant decrease in mean 
      CMT was observed during the follow-up period. An increase in mean IOP was 
      observed in the first 2mo after DEX therapy. The mean number of injections of the 
      overall population during the 6mo was 1.3. A subgroup analysis showed no relevant 
      difference between phakic versus pseudophakic patients relative to measured 
      outcomes. There was no cataract progression during the follow-up period and no 
      adverse events reported. CONCLUSION: This real-life setting study shows that 
      intravitreal DEX implant is effective and safe. The timings of greater 
      therapeutic impact are concordant with previous studies and suggest that earlier 
      treatment with corticosteroids may have an additional benefit in naive patients.
CI  - International Journal of Ophthalmology Press.
FAU - Neves, Pedro
AU  - Neves P
AD  - Department of Ophthalmology, Centro Hospitalar de Setubal, Setubal 2910-549, 
      Portugal.
FAU - Ornelas, Mario
AU  - Ornelas M
AD  - Department of Ophthalmology, Centro Hospitalar de Setubal, Setubal 2910-549, 
      Portugal.
FAU - Matias, Ines
AU  - Matias I
AD  - Department of Ophthalmology, Centro Hospitalar de Setubal, Setubal 2910-549, 
      Portugal.
FAU - Rodrigues, Joao
AU  - Rodrigues J
AD  - Department of Ophthalmology, Hospital Beatriz Angelo, Loures 2674-514, Portugal.
FAU - Santos, Margarida
AU  - Santos M
AD  - Department of Ophthalmology, Hospital da Luz Setubal, Setubal 2900-722, Portugal.
FAU - Dutra-Medeiros, Marco
AU  - Dutra-Medeiros M
AD  - Department of Ophthalmology, Centro Hospitalar Lisboa Central, Faculdade de 
      Ciencias Medicas, NOVA University of Lisbon, Lisbon 1990-237, Portugal.
FAU - Martins, David
AU  - Martins D
AD  - Department of Ophthalmology, Hospital da Luz Setubal, Setubal 2900-722, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20211018
PL  - China
TA  - Int J Ophthalmol
JT  - International journal of ophthalmology
JID - 101553860
PMC - PMC8482000
OTO - NOTNLM
OT  - anti-VEGF therapy
OT  - dexamethasone intravitreal implant
OT  - diabetic macular edema
OT  - naive eyes
OT  - steroids
EDAT- 2021/10/21 06:00
MHDA- 2021/10/21 06:01
PMCR- 2021/10/18
CRDT- 2021/10/20 06:46
PHST- 2020/07/24 00:00 [received]
PHST- 2021/01/05 00:00 [accepted]
PHST- 2021/10/20 06:46 [entrez]
PHST- 2021/10/21 06:00 [pubmed]
PHST- 2021/10/21 06:01 [medline]
PHST- 2021/10/18 00:00 [pmc-release]
AID - ijo-14-10-1571 [pii]
AID - 10.18240/ijo.2021.10.15 [doi]
PST - epublish
SO  - Int J Ophthalmol. 2021 Oct 18;14(10):1571-1580. doi: 10.18240/ijo.2021.10.15. 
      eCollection 2021.